Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, May 5 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND)
today announced it will host a conference call for its Q1 2011
financial results and hold an Annual & Special Meeting of Shareholders
on Thursday, May 12, 2011.
Q1 2011 CONFERENCE CALL
WHEN: THURSDAY, MAY 12, 2011 AT 8:30 A.M. ET
CONFERENCE CALL / WEBCAST: You can join the call by dialling 647-427-7450 or 1-888-231-8191. A
live audio webcast will be available through http://www.cipherpharma.com or http://www.newswire.ca. An archived replay of the webcast will be available for 365 days.
ANNUAL & SPECIAL MEETING OF SHAREHOLDERS
Thursday, May 12, 2011 at 11:00 A.m. ET.
Toronto Board of Trade
1 First Canadian Place
WEBCAST: The meeting will be webcast live. To access the webcast go to www.cipherpharma.com or http://www.newswire.ca. Please connect at least 15 minutes prior to the start of the meeting
to ensure adequate time for any software download that may be required
to join the webcast. An archived replay of the webcast will be
available for 365 days.
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals is a commercial-stage drug development company
focused on commercializing novel formulations of successful, currently
marketed molecules using advanced drug delivery technologies. Cipher's
strategy is to in-license products that incorporate proven drug
delivery technologies and advance them through the clinical development
and regulatory approval stages, after which the products are
out-licensed to international partners. Because Cipher's products are
based on proven technology platforms applied to currently marketed
drugs, they are expected to have lower approval risk, shorter
development timelines and significantly lower development costs. The
Company's lead compound is being marketed in the United States by Kowa
Pharmaceuticals America under the label Lipofen®. Cipher's second
product, an extended-release version of the pain reliever tramadol,
received FDA approval in May 2010 and the Company's third product, a
novel formulation of the acne treatment isotretinoin, is in its final
Phase III safety study.
Cipher is listed on the Toronto Stock Exchange under the symbol 'DND'
and has approximately 24 million shares outstanding. For more
information, please visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.
For further information: